Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EVP AND CFO | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 70,784 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Tax withholding · Disposed 388 · Balance 70,784 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 9,332 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,332 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2026. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 2,200 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,200 |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 388 | $110.36 | $42,819.68 |
DisclosureSEC source: 0001805099-26-000008 · form4-09032026_100959.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,784 Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 21:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 2,200 | $91.50 | $201,300.00 |
DisclosureSEC source: 0001805099-26-000006 · form4-04272026_090443.xml · nonDerivative · entry 2 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 2,200 Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 21:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | OtherCommon shares without par value | 8,909 | $92.04 | $819,984.36 |
DisclosureSEC source: 0001805099-26-000006 · form4-04272026_090443.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Profit Sharing Trust Disclosed balance after: 9,276 F1 · balance_after: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2026. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,441 | $116.26 | $865,090.66 |
DisclosureSEC source: 0001805099-26-000004 · form4-03042026_120355.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,172 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 115,413 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001805099-26-000002 · form4-02262026_100226.xml · derivative · entry 3 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,413 Underlying: Common Shares · 115,413 shares Expires 2036-02-23 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,471 on February 24, 2027, 38,471 on February 24, 2028, and 38,471 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 27,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001805099-26-000002 · form4-02262026_100226.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,613 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 387 | $132.66 | $51,339.42 |
DisclosureSEC source: 0001415889-25-023586 · form4-09032025_090923.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,616 Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 21:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,550 | $134.55 | $746,758.05 |
DisclosureSEC source: 0001415889-25-021451 · form4-08112025_090800.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,003 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.551 to $134.58, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,908 | $135.87 | $666,849.96 |
DisclosureSEC source: 0001415889-25-006741 · form4-03052025_120306.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EVP AND CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,553 Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 83,783 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005885 · form4-02272025_100252.xml · derivative · entry 3 Boudreau Philip P · CIK 0001805099 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,783 Underlying: Common Shares · 83,783 shares Expires 2035-02-24 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 27,927 on February 25, 2026, 27,928 on February 25, 2027, and 27,928 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:46 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 22,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005885 · form4-02272025_100252.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,461 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 387 | $113.27 | $43,835.49 |
DisclosureSEC source: 0001415889-24-022823 · form4-09042024_100951.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,966 Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,738 | $120.05 | $208,646.90 |
DisclosureSEC source: 0001415889-24-006402 · form4-03042024_110324.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · SENIOR VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,353 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 86,519 | $0.00 Strike: $116.98 | $0.00 |
DisclosureSEC source: 0001415889-24-005080 · form4-02232024_100223.xml · derivative · entry 3 Boudreau Philip P · CIK 0001805099 · SENIOR VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,519 Underlying: Common Shares · 86,519 shares Expires 2034-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 28,839 on February 21, 2025, 28,840 on February 21, 2026, and 28,840 on February 21, 2027. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 23,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005080 · form4-02232024_100223.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · SENIOR VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,091 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 10,223 | $0.00 Strike: $103.18 | $0.00 |
DisclosureSEC source: 0001415889-23-013036 · form4-09062023_100916.xml · derivative · entry 3 Boudreau Philip P · CIK 0001805099 · SENIOR VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,223 Underlying: Common Shares · 10,223 shares Expires 2033-08-31 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,407 on September 1, 2024, 3,408 on September 1, 2025, and 3,408 on September 1, 2026. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013036 · form4-09062023_100916.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · SENIOR VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,067 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 22:55 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,000 | $106.00 | $848,000.00 |
DisclosureSEC source: 0001415889-23-010065 · form4-06202023_100642.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,447 F1 · shares: The sale transaction was made pursuant to a Rule 10b5-1(c) plan adopted on February 24, 2023. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,477 | $99.77 | $147,360.29 |
DisclosureSEC source: 0001415889-23-003894 · form4-03032023_120354.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,447 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 19,149 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003046 · form4-02222023_110238.xml · derivative · entry 3 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,149 Underlying: Common Shares · 19,149 shares Expires 2033-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,383 on February 17, 2024, 6,383 on February 17, 2025, and 6,383 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,855 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003046 · form4-02222023_110238.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,924 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,192 | $122.41 | $145,912.72 |
DisclosureSEC source: 0001415889-22-002186 · form4-03022022_040307.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,069 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 01:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 966 | $116.79 | $112,819.14 |
DisclosureSEC source: 0001415889-22-001730 · form4-02232022_050218.xml · nonDerivative · entry 2 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,261 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 24,938 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001730 · form4-02232022_050218.xml · derivative · entry 4 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,938 Underlying: Common Shares · 24,938 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,312 on February 18, 2023, 8,313 on February 18, 2024, and 8,313 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 5,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001730 · form4-02232022_050218.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,227 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 22:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,000 | $126.49 | $1,011,920.00 |
DisclosureSEC source: 0001415889-21-004996 · form4-10272021_031057.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,876 Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 23:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 704 | $121.58 | $85,592.32 |
DisclosureSEC source: 0001415889-21-001197 · form4-03022021_030354.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,876 Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 23:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 937 | $123.04 | $115,288.48 |
DisclosureSEC source: 0001415889-21-000885 · form4-02232021_030207.xml · nonDerivative · entry 2 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,580 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 25,613 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000885 · form4-02232021_030207.xml · derivative · entry 4 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,613 Underlying: Common Shares · 25,613 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,537 on February 19, 2022, 8,538 on February 19, 2023, and 8,538 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 4,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000885 · form4-02232021_030207.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,517 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 943 | $128.23 | $120,920.89 |
DisclosureSEC source: 0001415889-21-000750 · form4-02182021_020216.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 22:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,600 | $82.00 | $869,200.00 |
DisclosureSEC source: 0001179110-20-003729 · edgar.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,463 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.